Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF- antagonists
| Autor: | Kenneth G. Saag, M. Burgess, D. Shatin, A. Xie, Carolyn K. Martin, J. M. Kramer, Nivedita M. Patkar, M. M. Braun, Jeffrey R. Curtis |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Article Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Cohort Studies Crohn Disease Rheumatology Internal medicine medicine Humans Pharmacology (medical) Cumulative incidence Adverse effect Heart Failure Tumor Necrosis Factor-alpha business.industry Incidence (epidemiology) Antibodies Monoclonal Number needed to harm Middle Aged medicine.disease Infliximab United States Surgery Antirheumatic Agents Immunoglobulin G Rheumatoid arthritis Relative risk Female business medicine.drug |
| Zdroj: | Rheumatology. 46:1688-1693 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/kem212 |
| Popis: | Objectives. New onset heart failure (HF) has been associated with the use of TNF-� antagonists etanercept and infliximab based upon spontaneous adverse event reports. HF clinical trials of these agents were stopped early due to futility or worsening of existing HF. A potential association between etanercept and infliximab and new onset HF has been studied minimally at a population level. Methods. Using administrative claims from a large U.S. health care organization, we identified rheumatoid arthritis (RA) and Crohn’s disease (CD) patients receiving infliximab or etanercept (exposed), and comparator cohorts of RA and CD patients receiving non-biologic immunosuppressives (unexposed). We studied adults |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|